Researchers explored the effect of adding concurrent local therapy to tebentafusp in patients with metastatic uveal melanoma after progression.
IDEAYA Biosciences recently presented positive Phase 2 clinical data at ESMO 2025, showing darovasertib achieved robust tumor shrinkage and eye preservation in patients with primary uveal melanoma, a ...
The MarketWatch News Department was not involved in the creation of this content. Vyome's offering is a first-of-its-kind in a broader $20B potential addressable ocular inflammation market VT-1908 ...
ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better ...
The global uveal melanoma treatment market is poised for substantial growth, projected to reach a market valuation of USD 2.4 billion by 2033, up from USD 1.4 billion in 2023, reflecting a healthy ...
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 December 2024) The European Organisation for Research and Treatment of Cancer (EORTC), an independent clinical cancer research ...
The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to observation (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback